Gregory L. Beatty, MD, PhD, an associate professor of Hematology-Oncology, has received the 2022 Pancreatic Cancer Action Network (PanCAN) Precision Medicine Targeted Grant Extension, a bonus grant of $200,000, in addition to the one he was awarded in 2021, to fund research to utilize patients' tumors' molecular characteristics to help determine the best treatment options. Beatty has also been named one of six recipients of the Therapeutic Accelerator Collaborative Award, a new PanCAN initiative to bring together industry, academic scientists, and clinicians to understand and enhance the effects of a novel investigational treatment combination being tested, and to drive the biotechnology and pharmaceutical industry to prioritize pancreatic cancer. This $365,000 award will support Beatty's work in the development of novel immunotherapies for the treatment of pancreatic cancer.
Derek Oldridge, MD, PhD, an assistant professor of Pathology and Laboratory Medicine, has been recognized as an early career researcher by the Parker Institute for Cancer Immunotherapy (PICI) and as a 2022 Parker Bridge Fellow for his research on treatments for deadly brain cancers. Chosen on the basis of academic achievement, scientific approach, innovation, the significance of the proposed work to advance the field, and the promise of the research to advance the mission and goals of PICI, Oldridge, along with eight postdoctoral researchers from leading academic institutions, will share up to $4.5 million in fellowship and scholarship awards.
Kyle G. Rodino, PhD, an assistant professor of Pathology and Laboratory Medicine and assistant director of the Clinical Microbiology Laboratory, and Jalal B. Jalaly, MBBS, MS, an assistant professor of Clinical Pathology and Laboratory Medicine, have been included in the American Society for Clinical Pathology's (ASCP) "40 under Forty" list. This prestigious ASCP recognition program honors emerging leaders and innovators of pathology and laboratory medicine.
Darwin Ye, a PhD candidate in Cancer Biology training in the laboratory of Andy Minn, MD, PhD, at the Abramson Cancer Center, has been recognized by the Parker Institute for Cancer Immunotherapy (PICI) as a 2022 Parker Scholar. The award is given to graduate students and researchers who are entering their first postdoctoral appointments and are focused on ambitious, high-impact projects. Ye, whose project involves learning how cells become resistant to immunotherapy to inform design of more effective cancer clinical trials, is one of eight postdoctoral researchers from leading academic institutions to share up to $4.5 million in fellowship and scholarship awards.
